Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of JPY 2.52 trillion. The enterprise value is 3.16 trillion.

Market Cap	2.52T
Enterprise Value	3.16T

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.14% in one year.

Current Share Class	n/a
Shares Outstanding	1.79B
Shares Change (YoY)	-0.14%
Shares Change (QoQ)	+1.59%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	55.90%
Float	1.79B

Valuation Ratios

The trailing PE ratio is 49.86 and the forward PE ratio is 18.69. Astellas Pharma's PEG ratio is 0.19.

PE Ratio	49.86
Forward PE	18.69
PS Ratio	1.32
PB Ratio	1.67
P/TBV Ratio	n/a
P/FCF Ratio	16.00
P/OCF Ratio	12.96
PEG Ratio	0.19

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.33, with an EV/FCF ratio of 20.08.

EV / Earnings	62.34
EV / Sales	1.65
EV / EBITDA	7.33
EV / EBIT	13.62
EV / FCF	20.08

Financial Position

The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.55.

Current Ratio	1.13
Quick Ratio	0.79
Debt / Equity	0.55
Debt / EBITDA	1.93
Debt / FCF	5.28
Interest Coverage	13.16

Financial Efficiency

Return on equity (ROE) is 3.26% and return on invested capital (ROIC) is 5.98%.

Return on Equity (ROE)	3.26%
Return on Assets (ROA)	4.21%
Return on Invested Capital (ROIC)	5.98%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	129.61M
Profits Per Employee	3.44M
Employee Count	14,754
Asset Turnover	0.55
Inventory Turnover	1.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.61% in the last 52 weeks. The beta is 0.13, so Astellas Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	-9.61%
50-Day Moving Average	1,419.55
200-Day Moving Average	1,586.29
Relative Strength Index (RSI)	50.14
Average Volume (20 Days)	6,597,230

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of JPY 1.91 trillion and earned 50.75 billion in profits. Earnings per share was 28.24.

Revenue	1.91T
Gross Profit	1.56T
Operating Income	232.55B
Pretax Income	31.24B
Net Income	50.75B
EBITDA	431.68B
EBIT	232.55B
Earnings Per Share (EPS)	28.24

Full Income Statement

Balance Sheet

The company has 188.37 billion in cash and 831.43 billion in debt, giving a net cash position of -643.05 billion or -359.23 per share.

Cash & Cash Equivalents	188.37B
Total Debt	831.43B
Net Cash	-643.05B
Net Cash Per Share	-359.23
Equity (Book Value)	1.51T
Book Value Per Share	845.21
Working Capital	139.74B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 194.51 billion and capital expenditures -37.00 billion, giving a free cash flow of 157.51 billion.

Operating Cash Flow	194.51B
Capital Expenditures	-37.00B
Free Cash Flow	157.51B
FCF Per Share	87.99

Full Cash Flow Statement

Margins

Gross margin is 81.74%, with operating and profit margins of 12.16% and 2.65%.

Gross Margin	81.74%
Operating Margin	12.16%
Pretax Margin	1.63%
Profit Margin	2.65%
EBITDA Margin	22.57%
EBIT Margin	12.16%
FCF Margin	8.24%

Dividends & Yields

This stock pays an annual dividend of 78.00, which amounts to a dividend yield of 5.54%.

Dividend Per Share	78.00
Dividend Yield	5.54%
Dividend Growth (YoY)	5.71%
Years of Dividend Growth	9
Payout Ratio	254.19%
Buyback Yield	0.14%
Shareholder Yield	5.68%
Earnings Yield	2.01%
FCF Yield	6.25%

Dividend Details

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 2.1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.1
Piotroski F-Score	n/a